Business
Senseonics Announces Initiation of European Commercial Efforts by Partner Ascensia Diabetes Care
GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and
About this update from Senseonics Holdings, Inc.
[{"type":"text","content":" GERMANTOWN, Md.--(BUSINESS WIRE)--\nSenseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Ascensia Diabetes Care (Ascensia) has commenced sales and marketing activities for the Eversense® XL CGM system in key European markets as of today, as part of their strategic partnership announced in August, 2020.\n\n“Today, we are extremely excited to see Ascensia, a global leader in the diabetes technology space, begin distribution of the Eversense XL in these key European markets. We are confident our shared goal of bringing our advanced long-term solution to more people with diabetes will be accomplished through Ascensia’s high level of commitment to our products and to patients and healthcare providers,” said Tim Goodnow, PhD, President and CEO of Senseonics. “Today further strengthens our collaboration and shows the commitment of our combined organizations to provide patients with an implantable sensor that gives them continuous glucose readings for up to 180 days. Ascensia’s global infrastructure and strong commercial experience alongside our focus on innovation, product development and production will enhance value for all our stakeholders.”\n\nUnder terms of the commercial agreement, today Ascensia initiates distribution of the Eversense XL System in Germany, Italy, The Netherlands, Poland, Spain and Switzerland. In the US, Ascensia is already providing sales support for the original Eversense® CGM system.\n\nAscensia Diabetes Care is a global specialist diabetes care company that is dedicated to helping people living with diabetes. It is a leader in the blood glucose monitoring market with its CONTOUR portfolio of systems that are known for their accuracy and ease of use. Ascensia markets its devices in over 125 countries across the world. The Switzerland based company is owned by PHC Holdings Corporation Ltd, a KKR portfolio company.\n\nEversense XL is the only CGM providing continuous glucose readings for up to 180 days with a single sensor in persons age 18 and older in the European market. The Eversense CGM System in the US provides continuous glucose readings for up to 90 days with a single sensor in persons age 18 and older. Inserted un...